| pubmed-article:19642587 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19642587 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:19642587 | lifeskim:mentions | umls-concept:C0040615 | lld:lifeskim |
| pubmed-article:19642587 | lifeskim:mentions | umls-concept:C1517004 | lld:lifeskim |
| pubmed-article:19642587 | lifeskim:mentions | umls-concept:C1701186 | lld:lifeskim |
| pubmed-article:19642587 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19642587 | pubmed:dateCreated | 2009-7-31 | lld:pubmed |
| pubmed-article:19642587 | pubmed:abstractText | The metabolism and pharmacokinetics of a new neurotensine-derived dipeptide drug dilept (N-caproyl-L-prolyltyrosine methyl ester) and its tentative metabolites after intravenous and peroral administration of the parent drug and its tabletized form in rats have been studied by HPLC-ESI(-)-MS/MS method. It is established that unchanged dilept (detected in the blood plasma for no less than 30 min) as well as N-caproyl-L-proline and N-caproyl-L-prolyl-L-tyrosine (both detected in the blood over more than 4 h) are the major metabolites in the bloodstream upon peroral administration of the drug. The proposed structures of metabolites were confirmed by countersynthesis. Dilept and N-caproyl-L-prolyl-L-tyrosine penetrate through the blood - brain barrier. The drug is rapidly absorbed, distributed, and metabolized in the rat organism. Peroral administration of dilept in rats in the form of tablets (at a dose of 200 mg/kg) resulted in a significant increase in intestinal absorption, as evidenced by a 22% improvement in the bioavailability, whereas dilept alone showed an absolute bioavailability of less than 1%. | lld:pubmed |
| pubmed-article:19642587 | pubmed:language | rus | lld:pubmed |
| pubmed-article:19642587 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19642587 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19642587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19642587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19642587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19642587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19642587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19642587 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19642587 | pubmed:issn | 0869-2092 | lld:pubmed |
| pubmed-article:19642587 | pubmed:author | pubmed-author:OstrovskaiaR... | lld:pubmed |
| pubmed-article:19642587 | pubmed:author | pubmed-author:ZherdevV PVP | lld:pubmed |
| pubmed-article:19642587 | pubmed:author | pubmed-author:SeredeninS... | lld:pubmed |
| pubmed-article:19642587 | pubmed:author | pubmed-author:Bo?koS SSS | lld:pubmed |
| pubmed-article:19642587 | pubmed:author | pubmed-author:GudashevaT... | lld:pubmed |
| pubmed-article:19642587 | pubmed:author | pubmed-author:AppolonovaS... | lld:pubmed |
| pubmed-article:19642587 | pubmed:author | pubmed-author:MesonzhnikN... | lld:pubmed |
| pubmed-article:19642587 | pubmed:author | pubmed-author:RodchenkovG... | lld:pubmed |
| pubmed-article:19642587 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19642587 | pubmed:volume | 72 | lld:pubmed |
| pubmed-article:19642587 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19642587 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19642587 | pubmed:pagination | 16-21 | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:meshHeading | pubmed-meshheading:19642587... | lld:pubmed |
| pubmed-article:19642587 | pubmed:articleTitle | [Experimental pharmacokinetics of the new neurotensine-derived antipsychotic drug dilept]. | lld:pubmed |
| pubmed-article:19642587 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19642587 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:19642587 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
